You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股隨內地同業跌 歌禮、三生及藥明生物挫7%-8.5%
內地生物醫藥及疫苗板塊今天跌2.2%。本港相關股今天也普遍隨大市下跌,尤其是藥明生物(02269.HK)沽壓最大,股價三連跌,最低見54.6元,現報55元,下挫8.5%,為最傷藍籌。藥明康德(02359.HK)也三連跌,最低見103.2元,現報103.7元,續跌3.5%。 三生製藥(01530.HK)三連挫,報5.46元,續挫7.6%。歌禮製藥(01672.HK)今早高開2.3%報4.8元欠承接,掉頭低見4.31元,現報4.37元,倒跌6.8%。開拓藥業(09939.HK)今早高見26元(受制10天線26.14元),掉頭低見23.55元,現報24.15元,倒跌5.3%。復星醫藥(02196.HK)高開1%報33.5元欠承接,掉頭低見30.65元,現報31.25元,倒跌5.7%。 康希諾生物(06185.HK)反覆三連跌,今天高低見100.3元/96.3元,現報96.5元,續跌3.2%。金斯瑞生物(01548.HK)及信達生物(01801.HK)跌逾4%,報21.3元及24.85元。 恆指受科指及工商分類指數急挫3.9%及3.5%拖累,午後低見20,530,現報20,571,下挫373點或1.8%,成交額761億元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account